Dr. Reddy introduces Bupropion Hydrochloride ER tablets

Dr. Reddy’s Laboratories Limited has announced the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban (Bupropion Hydrochloride) Extended-Release Tablets, approved by the U.S. Food and Drug Administration (USFDA).

The Zyban brand and generic had U.S. sales of approximately USD 5.4 million MAT for the most recent twelve months ending in June 2019 according to IQVIA Health.

Dr. Reddy's Bupropion Hydrochloride Extended-Release Tablets, USP (SR) are available as 150 mg dosage strength in bottle count sizes of 60. Although Bupropion Hydrochloride extended-release tablets (SR) are not indicated for treatment of depression, it contains the same active ingredient as the antidepressant medications.

Last month, the company had launched Vigabatrin Powder for Oral Solution, USP in 500 mg per packet, a therapeutic equivalent generic version of Sabril (vigabatrin) Powder for Oral Solution, USP, approved by the USFDA. Also, it had launched Versavo (bevacizumab), a biosimilar of Roche's Avastin in India, indicated for the treatment of several types of cancers.

Dr. Reddy’s Lab has three businesses namely - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APls, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

On Thursday, the stock of Dr. Reddy’s opened at Rs. 2,620.00 During the day, it had touched an intraday high of Rs. 2,684.20. At closing time, the stock was trading at Rs. 2,682.00, up by 3.09 percent on BSE.